List of Excipients in Branded Drug FROVATRIPTAN SUCCINATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	CELLULOSE, MICROCRYSTALLINE
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	HYPROMELLOSES
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	LACTOSE
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	MAGNESIUM STEARATE
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	POLYETHYLENE GLYCOL 3000
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	SILICON DIOXIDE
Endo USA Inc	FROVATRIPTAN SUCCINATE	frovatriptan succinate	0603-3718	SODIUM STARCH GLYCOLATE TYPE A POTATO

Generic Drugs Containing FROVATRIPTAN SUCCINATE

Company	Ingredient	NDC	Excipient
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	ANHYDROUS LACTOSE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	CELLULOSE, MICROCRYSTALLINE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	HYPROMELLOSE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	LACTOSE MONOHYDRATE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	MAGNESIUM STEARATE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	SILICON DIOXIDE
Glenmark Pharmaceuticals Inc USA	frovatriptan succinate	68462-694	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in FROVATRIPTAN SUCCINATE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	SILICON DIOXIDE
1	SODIUM STARCH GLYCOLATE TYPE A POTATO

Excipient Strategy and Commercial Opportunities for Frovatriptan Succinate

Last updated: February 25, 2026

What is the Excipient Strategy for Frovatriptan Succinate?

Frovatriptan succinate’s formulation primarily targets oral tablets for the acute treatment of migraine. The excipient strategy involves selecting substances that support drug stability, optimize bioavailability, and ensure patient tolerability.

Key excipients used in Frovatriptan succinate formulations:

• Binders: Microcrystalline cellulose (MCC) forms the core matrix, ensuring tablet integrity.
• Disintegrants: Cross-linked sodium carboxymethyl cellulose (croscarmellose sodium) accelerates disintegration.
• Lubricants: Magnesium stearate reduces friction during tablet compression.
• Fillers: Lactose monohydrate enhances volume and absorption properties.
• Coatings: Film coatings with hydroxypropyl methylcellulose (HPMC) improve stability, mask taste, and protect against environmental factors.

Choice of excipients emphasizes stability, manufacturability, and patient compliance. For extended-release or novel delivery forms, additional excipients like mucoadhesive polymers or lipids could be considered.

What Are the Commercial Opportunities Linked to Excipient Innovation?

Innovation in excipient formulation can create differentiation and expand market share. Opportunities include:

1. Extended-Release Formulations

Designing sustained-release tablets can extend dosing intervals from once to twice daily. Excipient strategies involve hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC) or ethylcellulose. These formulations potentially improve patient adherence and reduce misuse.

2. Orally Disintegrating Tablets (ODTs)

Evolving consumer preferences favor ODT formulations. Using superdisintegrants and taste-masking agents, companies can tap into markets with patients who have swallowing difficulties, such as elderly or pediatric populations.

3. Novel Delivery Platforms

Transdermal patches, buccal films, or nasal sprays could bypass gastrointestinal issues. Custom excipient blends, including mucoadhesive polymers or penetration enhancers, enable these formats.

4. Generic Formulation Optimization

Patent expirations open opportunities for generics. Innovative excipient choices can improve bioequivalence, stability, or manufacturing efficiency, offering competitive advantages.

5. Formulation Compatibility and Stability Enhancements

Developing formulations resistant to humidity, heat, or photodegradation increases shelf life and reduces costs related to storage and transportation.

Market Outlook and Trends

• The global migraine drugs market was valued at USD 6.4 billion in 2020 and is projected to grow at a CAGR of 4.4% through 2028 (Fortune Business Insights, 2022).
• Frovatriptan succinate competes in a market dominated by sumatriptan and rizatriptan but holds niche advantages for its long half-life.
• Excipient innovation can significantly differentiate products in biosimilar, generic, and branded markets, particularly in emerging economies.

Regulatory and Manufacturing Considerations

• Excipient selection impacts regulatory approval pathways. US FDA and EMA guidelines emphasize excipient safety, purity, and compatibility.
• Standardized excipients streamline manufacturing, but novel excipients require extensive safety and stability data.
• Cost efficiencies favor the use of widely available excipients; however, innovation investments may provide premium pricing.

Summary of Key Excipient-Related Opportunities

Opportunity	Focus Areas	Potential Benefits
Extended-release tablets	Hydrophilic polymers, matrix-forming excipients	Improved adherence, competitive edge
Orally disintegrating formulations	Superdisintegrants, taste-masking agents	Enhanced patient compliance
Alternative delivery formats	Mucoadhesive polymers, penetration enhancers	Market expansion, addressing unmet needs
Stability improvements	Antioxidants, light-protective excipients	Longer shelf life, reduced waste
Cost-effective generic formulations	Common excipients, process optimization	Competitive pricing, market share growth

Key Takeaways

• Excipient selection critical for Frovatriptan succinate formulation stability, bioavailability, and patient acceptance.
• Innovation avenues include extended-release, disintegrating tablets, and alternative delivery methods.
• Market growth driven by migraine prevalence and demand for convenient formulations.
• Regulatory compliance hinges on excipient safety and stability data.
• Strategic excipient development can offer competitive advantages in growth and differentiation.

Frequently Asked Questions

1. What are the main excipients in Frovatriptan succinate tablets?
   Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, and hydroxypropyl methylcellulose.

2. How can excipient innovation improve Frovatriptan formulations?
   Through extended-release profiles, better taste masking, enhanced stability, and alternative delivery platforms.

3. Are alternative delivery formats feasible for Frovatriptan?
   Yes; mucoadhesive patches, nasal sprays, and orally disintegrating tablets are under exploration for migraine drugs.

4. What regulatory considerations influence excipient choice?
   Excipients must meet safety, purity, and compatibility standards outlined by agencies like the FDA and EMA.

5. What is the outlook for excipient-driven differentiation in the Frovatriptan market?
   High, especially with formulations targeting unmet patient needs, adherence improvement, and competitive pricing.

---

References

[1] Fortune Business Insights. (2022). Migraine Drugs Market Size, Share & Industry Analysis.
[2] U.S. Food and Drug Administration. (2020). Guidance for Industry: Oral Drug Products—Development and Evaluation.